Sanofi (SNY)
(Delayed Data from NSDQ)
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 4:22 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 4:22 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Geron Stock Rises after Positive Interim Update on Imetelstat
by Zacks Equity Research
Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.
Forget Novartis, Buy These Two Pharma Stocks Instead
by Arpita Dutt
With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
by Arpita Dutt
Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
VIVUS to Regain Commercial Rights for Stendra from Sanofi
by Zacks Equity Research
VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
by Arpita Dutt
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout
by Joseph Lu
Shares of Flexion Therapeutics (FLXN) soared on Thursday, up 36% to $26.80 per share following reports that French drug giant Sanofi (SNY) is in talks to purchase the biotech company for more than $1 billion in cash.
Merck Closes Acquisition of Controlling Stake in Vallee S.A
by Zacks Equity Research
Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Will Sanofi (SNY) Prove to be a Suitable Value Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.
What are Sanofi's (SNY) Strengths and Challenges in 2017?
by Zacks Equity Research
We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
by Zacks Equity Research
We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.
Amgen's Repatha Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
by Zacks Equity Research
We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
by Zacks Equity Research
Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
by Zacks Equity Research
Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.
Ionis Pharma Lipid Disorder Candidate Positive in Phase III
by Zacks Equity Research
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
by Arpita Dutt
Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.